← Back to Clinical Trials
Recruiting NCT06543108

NCT06543108 Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06543108
Status Recruiting
Phase
Sponsor Hunan Cancer Hospital
Condition Gastric Cancer
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2024-01-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type OBSERVATIONAL
Interventions
The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2024-01-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project aims to comprehensively analyze the diagnostic efficacy of SUVmax, SUVean, TLG, MTV, etc. in gastric cancer through 18F-FAPI-04 PET/CT imaging combined with serum tumor markers and other methods, and construct a molecular imaging diagnostic model for gastric cancer; Next, analyze the diagnostic efficacy of 18F-FAPI-04 PET/CT and PET/MR multimodal imaging in evaluating SUVmax, PET/CT-PCI, and PET/MR-PCI for gastric cancer peritoneal metastasis, and construct a molecular imaging diagnostic model for gastric cancer peritoneal metastasis; Exploring the clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer.

Eligibility Criteria

Inclusion Criteria: 1. Age over 18 years old; 2. Diagnosed as a patient with gastric cancer; 3. Receive FAPI PET/CT and FDG PET/CT imaging within one week; 4. Perform serum tumor marker testing one week before and after scanning Exclusion Criteria: 1. History of other malignant tumors; 2. Patients with severe infections, severe underlying diseases such as heart, kidney, and liver; 3. Patients with contraindications for PET-CT examination, poor physical condition, and inability to tolerate the examination; 4. Patients with unorganized pathology or incomplete clinical data

Contact & Investigator

Central Contact

Hui Ye

✉ yuxin75831@163.com

📞 86-13755117105

Frequently Asked Questions

Who can join the NCT06543108 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06543108 currently recruiting?

Yes, NCT06543108 is actively recruiting participants. Contact the research team at yuxin75831@163.com for enrollment information.

Where is the NCT06543108 trial being conducted?

This trial is being conducted at Changsha, China.

Who is sponsoring the NCT06543108 clinical trial?

NCT06543108 is sponsored by Hunan Cancer Hospital. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology